<DOC>
	<DOCNO>NCT01616186</DOCNO>
	<brief_summary>This phase II trial follow completion phase I UCSF trial everolimus sorafenib Renal Cell Carcinoma ( RCC ) . This trial patient treatment RCC . This trial 2/3 patient get everolimus/sorafenib treatment 1/3 get sunitinib , FDA approve RCC drug . All three drug approve advanced RCC use individually , combination everolimus sorafenib RCC approve FDA .</brief_summary>
	<brief_title>Everolimus/Sorafenib Sunitinib Patients With Metastatic Renal Cell Carcinoma ( RCC )</brief_title>
	<detailed_description>In phase I study combination everolimus sorafenib , clinical benefit observe patient prior systemic therapy . There evidence pharmacokinetic interaction acceptable toxicity dosage sorafenib 400 mg twice daily ( BID ) everolimus 5 mg daily . Based data need effective front-line therapy renal cell carcinoma , plan investigate regimen patient undergone prior therapy . A sunitinib arm include concurrent reference help provide guideline activity level toxicity would meaningful move forward phase III study . Therefore , study design non-comparative investigation patient randomize 2:1 ratio everolimus/sorafenib sunitinib , respectively .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Histologically cytologicallyconfirmed renal cell carcinoma , unresectable metastatic follow histology : clear cell , papillary , chromophobic , oncocytic , unclassified , mixed . A component clear cell histology must present . Tumors pure collect duct histology eligible . 2 . Cytoreductive nephrectomy allow require 3 . Evidence RECISTdefined measurable disease ( lesion accurately measure least one dimension long diameter ≥ 20mm use conventional technique ≥ 10 mm spiral CT scan ) 4 . Male female least 18 year old 1 . Female patient must either surgically sterile postmenopausal , childbearing potential must negative pregnancy test ( serum urine ) prior enrollment agree use effective barrier contraception period therapy , 3 month end treatment/end participation study . Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , therefore consider effective study . 2 . Male patient must surgically sterile must agree use effective contraception period therapy , 3 month end treatment/end participation study . 3 . The definition effective contraception base judgment investigator . 5 . ECOG performance status 01 6 . Adequate bone marrow function : 1 . ANC ≥ 1500/uL 2. platelet count ≥ 100,000/uL 3. hemoglobin ≥ 9.0 g/dL 7 . Adequate hepatic function : 1 . Total bilirubin ≤ 1.5 X ULN 2 . AST ( SGOT ) ≤ 2.5 X ULN 3 . ALT ( SGPT ) ≤ 2.5 X ULN 8 . Adequate renal function determine either : 1 . Calculated measured creatinine clearance ≥ 40 mL/min ( calculated creatinine clearance , CockroftGault equation use ) Modified CockcroftGault formula : ( ( 140 age ( yr ) ) x ( actual weight ( kg ) ) ) / ( 72 x serum creatinine ( mg/dl ) ) * Multiply another factor 0.85 female 2 . Serum creatinine ≤ 1.5 X ULN 9 . Able swallow oral medication 10 . Total fasting serum cholesterol ≤ 300 mg/dL 11 . Resolution preexist toxicity prior therapy NCI CTCAE V3.0 ≤ grade 1 ( exception hypertension , hypothyroidism ) 12 . Signed date informed consent document 13 . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . 14 . More 28 day since prior therapy , include investigational agent surgical procedure . EXCLUSION CRITERIA 1 . Collecting duct renal cell carcinoma exclude . Transitional cell carcinoma renal pelvis exclude . 2 . Prior systemic regimen renal cell carcinoma ( neoadjuvant therapy acceptable long include sunitinib , sorafenib , everolimus , temsirolimus ) . A prior therapy start stop four week therapy constitute prior systemic regimen . 3 . Prior surgery , radiation therapy , systemic therapy renal cell carcinoma within 4 week start study treatment . 4 . History known brain metastasis , spinal cord compression , carcinomatous meningitis , new evidence brain leptomeningeal disease screen CT MRI scan ( evaluation CNS disease require performed eligibility ) . 5 . Any follow within 6 month prior study drug administration : myocardial infarction , unstable severe angina , coronary peripheral artery bypass graft , NYHA functional Class II , III , IV congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism . 6 . Ejection fraction lower institutional low limit normal echocardiogram MUGA . 7 . Hypertension unable control medication blood pressure ≤ 150/90 . 8 . Hypothyroidism unable control medication FT4 outside normal limit . 9 . QTc prolongation ( QTc interval ≥ 480 msec ) clinically significant ECG abnormality . 10 . Known human immunodeficiency virus ( HIV ) acquire immune deficiency syndrome ( AIDS ) relate illness ( immunosuppressive effect therapy ) . Testing HIV absence history symptom require . 11 . Hepatitis B C ( risk reactivation ) . The following serology acceptable enrollment : HBsAg/antiHBc/antiHBs ; HBsAg/antiHBc+/antiHBs+ ; HBsAg/antiHBc/antiHBs+ . The following serology acceptable enrollment : HBsAg+/antiHBc+ ( IgM+/ ) /antiHBs . If following serology obtain , additional testing require ascertain patient 's hepatitis B status : HBsAg/antiHBc+/antiHBs . 12 . `` Currently active '' second malignancy nonmelanoma skin cancer . Patients consider `` currently active '' malignancy complete therapy consider less 30 % risk relapse . 13 . Current treatment another clinical trial . 14 . Pregnant breastfeeding . 15 . Chronic treatment systemic steroid immunosuppressive agent . 16 . On oral vitamin K antagonist medication ( except low dose warfarin ) ( anticoagulant allow ) . 17 . History malabsorption syndrome , disease significantly affect gastrointestinal function major resection stomach small bowel could interfere absorption , distribution , metabolism , excretion study drug . 18 . Any serious and/or unstable preexist medical , psychiatric , condition ( include lab abnormality ) could interfere subject safety obtain informed consent . Examples include uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN ( Note : optimal glycemic control achieve start trial therapy ) , nonhealing wound , severe infection , severe malnutrition , ventricular arrhythmia , active ischemic heart disease , chronic liver renal disease , active upper GI tract ulceration . 19 . Patients receive immunization attenuate live vaccine within one week study entry study period . Close contact receive attenuated live vaccine avoid treatment everolimus . Examples live vaccine include intranasal influenza , measles , mumps , rubella , oral polio , BCG , yellow fever , varicella TY21a typhoid vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Renal Cell Carcinoma</keyword>
</DOC>